Andrew Zloza
Assistant Professor, Division of Hematology, Oncology and Cell Therapy at Rush University Medical Center / Faculty at Harvard Medical School
Schools
- Harvard Medical School
Links
Biography
Harvard Medical School
Andrew Zloza, MD, PhD, is a tenure-track Assistant Professor in the Department of Internal Medicine, Division of Hematology, Oncology, and Cell Therapy.
Dr. Zloza earned his BS in Chemical Engineering at the Illinois Institute of Technology (IIT) as part of the IIT/Rush University Honors Program in Engineering and Medicine. He completed MD and PhD (Immunology/Microbiology) studies as part of the Rush Physician Scientist MD PhD Program. He further trained as a Ruth L. Kirschstein National Research Service Award (NRSA) postdoctoral fellow (NIH T32) in Cancer Immunology and Tumor Vaccine Research at The University of Chicago.
Prior to returning to Rush in 2018, Dr. Zloza served as the Section Chief of Surgical Oncology Research and founding Director of the Immune Monitoring Shared Resource at Rutgers Cancer Institute of New Jersey and as a tenure-track Assistant Professor in the Department of Surgery at Rutgers Robert Wood Johnson Medical School. Dr. Zloza directs a research group funded by NIH R01, R44 (SBIR), and industry-sponsored grants. His laboratory focuses on: 1) defining basic mechanisms by which pathogens and anti-pathogen vaccines alter the host immune response to cancer and 2) developing translational microbial-based cancer therapies (MBCTs) to improve patient outcomes. Towards this they create: 1) highly relevant and personalized humanized mouse models consisting of autologous patient-derived tissues and immune cells (i.e. from the same patient), and 2) novel biotechnologies (including specialized immuno-nanoparticles).
In recognition of his successes as a young investigator, Dr. Zloza has been awarded the 2015 Chambers-eBioscience Memorial Award by the American Association of Immunologists and a Junior Faculty Award at the 3rd Annual Immuno-Oncology Young Investigator’s Forum in 2017.
Research Areas
Cancer immunotherapy, microbial-based cancer therapies (MBCTs), “bugs as drugs”, cancer vaccines, immune-reconstituted patient-derived xenograft (PDX) mouse models, cancer immuno-nanoparticles
Education
MD, Rush Medical College
PhD, Rush Graduate College
BS, Illinois Institute of Technology
Read about executive education
Other experts
Popular Courses
Leading People and Teams
ESMT
Berlin, Germany
Nov 19
Private Equity: Investing and Creating Value
The Wharton School
Philadelphia, Pennsylvania, United States
Feb 2, 2025
The Positive Leader: Deep Change and Organizational Transformation
Stephen M. Ross School of Business
Ann Arbor, Michigan, United States
Dec 1
Looking for an expert?
Contact us and we'll find the best option for you.